Ardelyx, Inc.
ARDXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Ardelyx, Inc. focuses on Biotechnology services and products. Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. With a market capitalization of $1.28B, it sits in small-cap territory. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
Market Cap
$1.28B
Beta
0.60
P/E (TTM)
—
P/E (Fwd)
10.10
EPS (TTM)
$-0.24
EPS (Fwd)
$0.52
ROE
-39.5%
ROA
-5.1%
Cash
$238.1M
Total Debt
$234.1M
Free CF
$86,375
52W Change
17.9%
Annual Financials
Cash vs Debt
With $238.1M in cash and $234.1M in debt, ARDX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $86K in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -39.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $52.2M (2022) to $407.3M (2025), reflecting a 681% increase over the period.
The relatively low beta of 0.60 suggests ARDX is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Ardelyx, Inc. and its sector.